Generic Name: zanubrutinib
Brand Name: Brukinsa
Manufacturer: BeiGene, Ltd.
Therapeutic Area: Waldenström’s macroglobulinemia
Indications: For the treatment of patients with Waldenström’s macroglobulinemia (WM)
Manufacturer Requested Reimbursement Criteria1: For the treatment of patients with Waldenström’s macroglobulinemia (WM)
Submission Type: Initial
Tumour Type: Lymphoma
Project Status: Pending
Call for patient/clinician input open: March 23, 2021
Call for patient/clinician input closed: May 14, 2021
Anticipated Date: April 21, 2021
Fee Schedule1: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.